Evidence map›Paper›PMID 16012871›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2005

Comparison of the alpha-adrenoceptor-mediated effects of beta3-adrenoceptor ligands in rat pulmonary artery.

Véronique Leblais, Fabrice Pourageaud, M Dolores Ivorra, Roger Marthan, Bernard Muller

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.Journal of molecular and cellular cardiology · 2010
    Review
  6. Tools to study beta3-adrenoceptors.Naunyn-Schmiedeberg's archives of pharmacology · 2007
    Review
  7. Article
  8. Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor.Naunyn-Schmiedeberg's archives of pharmacology · 2006
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Véronique LeblaisLaboratoire de Pharmacologie de la Faculté de Pharmacie, Université Victor Segalen Bordeaux 2, Casier 83 Inserm, E356 146 rue Léo Saignat, Bordeaux cedex 33076, France. veronique.leblais@phcodyn.u-bordeaux2.fr
Fabrice Pourageaud
M Dolores Ivorra
Roger Marthan
Bernard Muller
Université de Bordeaux · FRGalen University · BZUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have recently shown that the beta-adrenoceptor ligands CGP 12177, bupranolol, and SR 59230A (aryloxypropanolamines), but not BRL 37344 and CL 316243 (phenylethanolamines), exhibit significant affinity for alpha1-adrenoceptors and that CGP 12177 displays partial agonist properties at alpha-adrenoceptors in rat pulmonary artery. In this study, bupranolol and SR 59230A were further evaluated for their potential alpha-adrenoceptor mediated effects (i.e., agonist and/or antagonist properties) in rat intralobar pulmonary artery and compared with BRL 37344 and CL 316243. Bupranolol induced a relaxation in phenylephrine-precontracted arteries, but had no effect in prostaglandin F2alpha(PGF2alpha) -precontracted ones. SR 59230A also elicited a relaxation in phenylephrine-precontracted arteries. In PGF2alpha -precontracted arteries, SR 59230A induced a contractile response that was insensitive to the irreversible alpha-adrenoceptor antagonist phenoxybenzamine. BRL 37344 at high concentrations, but not CL 316243, produced slight relaxation in both phenylephrine- and PGF2alpha -precontracted arteries. The contractile response to phenylephrine was antagonized by bupranolol and SR 59230A in a competitive manner (pA2: 6.38 and 7.08 respectively). The concentration-response curve to phenylephrine was also shifted to the right by BRL 37344 (mean pKb: 4.45), but not by CL 316243 (100 microM). This study indicates that the aryloxypropanolamine derivatives bupranolol and SR 59230A exhibit competitive antagonist, but no agonist properties on alpha1-adrenoceptors, SR 59230A also inducing alpha-adrenoceptor-independent contraction. Among the phenylethanolamines, BRL 37344 but not CL 316243, also exerts an antagonist effect on alpha1-adrenoceptors, with a much lower potency than the aryloxypropanolamines studied.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAdrenergic beta-AgonistsAdrenergic beta-AntagonistsAnimalsBupranololDioxolesEthanolaminesIn Vitro TechniquesLigandsMalePropanolaminesPulmonary ArteryRatsRats, WistarReceptors, Adrenergic, beta-3Vasodilation3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalateAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-AgonistsAdrenergic beta-AntagonistsBRL 37344BupranololDioxolesdisodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylateEthanolaminesLigandsPropanolaminesReceptors, Adrenergic, beta-3

Identifiers

PMID16012871
OpenAlexW2146019673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.